Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of ivabradine on cardiovascular events in patients with moderate-to-severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study.

Trial Profile

Effects of ivabradine on cardiovascular events in patients with moderate-to-severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms SHIFT
  • Sponsors IRIS; Servier
  • Most Recent Events

    • 27 Dec 2018 According to an Ono Pharmaceuticals media release, based on the data from SHIFT and J-SHIFT studies, the company has submitted in Japan an application for manufacturing and marketing approval of ivabradine hydrochloride (Ivabradine), for the treatment of patients with chronic heart failure with resting heart rate greater that or equal to 75 beats per minute in sinus rhythm.
    • 12 Oct 2017 Results assessing efficacy published in the European Journal of Heart Failure.
    • 01 Sep 2017 Results published in the Circulation: Heart Failure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top